Differential permeation of piroxicam-loaded PLGA micro/nanoparticles and their in vitro enhancement
Source abstract
Abstract
Piroxicam is a non-steroidal anti-inflammatory drug used for the treatment of musculoskeletal pain. The main problem encountered when piroxicam is administered orally is its gastric side-effect (ulcer, bleeding and holes in the stomach). Transmucosal delivery and encapsulation of piroxicam in biodegradable particles offer potential advantages over conventional oral delivery. The present study was aimed to develop an alternative to piroxicam-delivery which could overcome the direct contact of the drug at the mucosal membrane and its permeation through the mucosal membrane was studied. To achieve this, the piroxicam was encapsulated in Poly (lactide-co-glycolide) (PLGA) microparticles (size 1–4 μm, encapsulation efficiency 80–85 %) and nanoparticles (size 151.6 ± 28.6 nm, encapsulation efficiency 92.17 ± 3.08 %). Various formulation process parameters were optimised for the preparation of piroxicam-loaded PLGA nanoparticles of optimal size and encapsulation efficiency. Transmucosal permeability of piroxicam-loaded PLGA micro- and nanoparticles through the porcine oesophageal mucosa was studied. Using fluorescently labelled PLGA micro- and nanoparticles, size-dependent permeation was demonstrated. Furthermore, the effect of different permeation enhancers on the flux rate and permeability coefficient for the permeation of nanoparticles was investigated. The results suggested that amongst the permeation enhancers used the most efficient enhancement of permeation was observed with 10 mM sodium dodecyl sulphate.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Inhalation and Respiratory Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Adibkia K, Shadbad MRS, Nokhodchi A, Javadzedeh A, Barzegar-Jalali M, Barar J et al (2007) Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target 15:407–41610.1080/10611860701453125 ↗
2. Ahmed AR, Dashevsky A, Bodmeier R (2008) Reduction in burst release of PLGA microparticles by incorporation into cubic phase-forming systems. Eur J Pharm Biopharm 70:765–76910.1016/j.ejpb.2008.07.008 ↗
3. Attia MA, El-Gibaly I, Shaltout SE, Fetih GN (2004) Transbuccal permeation, anti-inflammatory activity and clinical efficacy of piroxicam formulated in different gels. Int J Pharm 276:11–2810.1016/j.ijpharm.2004.01.041 ↗
4. Bazzo GC, Lemos-Senna E, Pires ATN (2009) Poly(3-hydroxybutyrate)/chitosan/ketoprofen or piroxicam composite microparticles: preparation and controlled drug release evaluation. Carbohyd Polym 77:839–84410.1016/j.carbpol.2009.03.006 ↗
5. Bird AP, Faltinek JR, Shojaei AH (2001) Transbuccal peptide delivery: stability and in vitro permeation studies on endomorphin-1. J Control Release 73:31–3610.1016/S0168-3659(01)00246-2 ↗
6. Cone RA (1999) Mucus. In: Michael WS, Lamm E, McGhee JR, Mayer L, Mestecky J, Bienenstock J (eds) Mucosal immunology. Academic Press, San Diego, pp 43–64
7. Cone RA (2009) Barrier properties of mucus. Adv Drug Deliv Rev 61:75–8510.1016/j.addr.2008.09.008 ↗
8. Danhier F, Vroman B, Lecouturier N, Crokart N, Pourcelle V, Freichels H et al (2009) Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J Control Release 140:166–17310.1016/j.jconrel.2009.08.011 ↗
9. Davda J, Labhasetwar V (2002) Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 233:51–5910.1016/S0378-5173(01)00923-1 ↗
10. Diaz-Del Consuelo I, Jacques Y, Pizzolato GP, Guy RH, Falson F (2005) Comparison of the lipid composition of porcine buccal and esophageal permeability barriers. Arch Oral Biol 50:981–98710.1016/j.archoralbio.2005.04.008 ↗
11. Duncan G, Jess TJ, Mohamed F, Price NC, Kelly SM, van der Walle CF (2005) The influence of protein solubilisation, conformation and size on the burst release from poly(lactide-co-glycolide) microspheres. J Control Release 110:34–4810.1016/j.jconrel.2005.09.007 ↗
12. Florence AT (1997) The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res 14:259–146610.1023/A:1012029517394 ↗
13. Ganem-Quintanar A, Kalia YN, Falson-Rieg F, Buri P (1997) Mechanisms of oral permeation enhancement. Int J Pharm 156:127–14210.1016/S0378-5173(97)00193-2 ↗
14. Garcia X, Escribano E, Domenech J, Queralt J, Freixes J (2011) In vitro characterization and in vivo analgesic and anti-allodynic activity of PLGA-bupivacaine nanoparticles. J Nanopart Res 13:2213–222310.1007/s11051-010-9979-1 ↗
15. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G (2010) Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine 6:324–33310.1016/j.nano.2009.10.004 ↗
16. Hoogstraate AJ, Senel S, Cullander C, Verhoef J, Junginger HE, Boddé HE (1996) Effects of bile salts on transport rates and routes of FITC-labelled compounds across porcine buccal epithelium in vitro. J Control Release 40:211–22110.1016/0168-3659(95)00187-5 ↗
17. Horisawa E, Kubota K, Tuboi I, Sato K, Yamamoto H, Takeuchi H, Kawashima Y (2002) Size-dependency of dl-lactide/glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium. Pharm Res 19:132–13910.1023/A:1014260513728 ↗
18. Jasti BR, S Z, Mehta RC, Li X (2000) Permeability of antisense oligonucleotide through porcine buccal mucosa. Int J Pharm 208:35–3910.1016/S0378-5173(00)00543-3 ↗
19. Jin C, Bai L, Wu H, Teng Z, Guo G, Chen J (2008) Cellular uptake and radiosensitization of SR-2508 loaded PLGA nanoparticles. J Nanopart Res 10:1045–105210.1007/s11051-007-9336-1 ↗
20. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J (2007) Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 120:18–2610.1016/j.jconrel.2007.03.012 ↗
21. Lai SK, O’Hanlon DE, Harrold S, Man ST, Wang Y-Y, Cone R et al (2007) Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci USA 104:1482–148710.1073/pnas.0608611104 ↗
22. Lai SK, Wang Y-Y, Hanes J (2009) Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61:158–17110.1016/j.addr.2008.11.002 ↗
23. Lammers T, Hennink WE, Storm G (2008) Tumour-targeted nanomedicines: principles and practice. Br J Cancer 99:392–39710.1038/sj.bjc.6604483 ↗
24. Lamprecht A, Ubrich N, Hombreiro Pérez M, Lehr CM, Hoffman M, Maincent P (2000) Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int J Pharm 196:177–18210.1016/S0378-5173(99)00422-6 ↗
25. Lazzari S, Moscatelli D, Codari F, Salmona M, Morbidelli M, Diomede L (2012) Colloidal stability of polymeric nanoparticles in biological fluids. J Nanopart Res 14:92010.1007/s11051-012-0920-7 ↗
26. Madhav NVS, Shakya AK, Shakya P, Singh K (2009) Orotransmucosal drug delivery systems: a review. J Control Release 140:2–1110.1016/j.jconrel.2009.07.016 ↗
27. Mainardes RM, Evangelista RC (2005) PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 290:137–14410.1016/j.ijpharm.2004.11.027 ↗
28. Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaers AJ, Snyder PW et al (2002) Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 62:356–358
29. Nakada Y, Awata N, Nakamichi C, Sugimoto I (1988) The effect of additives on the oral mucosal absorption of human calcitonin in rats. J Pharmacobiodyn 11:395–40110.1248/bpb1978.11.395 ↗
30. Norris DA, Sinko PJ (1997) Effect of size, surface charge, and hydrophobicity on the translocation of polystyrene microspheres through gastrointestinal mucin. J Appl Polym Sci 63:1481–149210.1002/(SICI)1097-4628(19970314)63:11<1481::AID-APP10>3.0.CO;2-5 ↗
31. Oh CK, Ritschel WA (1990) Absorption characteristics of insulin through the buccal mucosa. Methods Find Exp Clin 12:275–279
32. Panyam J, Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55:329–34710.1016/S0169-409X(02)00228-4 ↗
33. Pérez-Artacho B, Gallardo V, Ruiz MA, Arias JL (2012) Maghemite/poly(d,l-lactide-co-glycolyde) composite nanoplatform for therapeutic applications. J Nanopart Res 14:76810.1007/s11051-012-0768-x ↗
34. Piao MG, Kim JH, Kim JO, Lyoo WS, Lee MH, Yong CS et al (2007) Enhanced oral bioavailability of piroxicam in rats by hyaluronate microspheres. Drug Dev Ind Pharm 33:485–49110.1080/03639040600865223 ↗
35. Pollauf EJ, Kim KK, Pack DW (2005) Small-molecule release from poly(d,l-lactide)/poly(d,l-lactide-co-glycolide) composite microparticles. J Pharm Sci 94:2013–202210.1002/jps.20408 ↗
36. Porta GD, Reverchon E (2008) Nanostructured microspheres produced by supercritical fluid extraction of emulsions. Biotechnol Bioeng 100:1020–103310.1002/bit.21845 ↗
37. Puthli S, Vavia P (2009) Stability studies of microparticulate system with piroxicam as model drug. AAPS PharmSciTech 10:872–88010.1208/s12249-009-9280-8 ↗
38. Raman C, Berkland C, Kim K, Pack DW (2005) Modeling small-molecule release from PLG microspheres: effects of polymer degradation and nonuniform drug distribution. J Control Release 103:149–15810.1016/j.jconrel.2004.11.012 ↗
39. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G (1990) Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with d,l-{alpha}-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 50:256–268
40. Richy F, Scarpignato C, Lanas A, Reginster J-Y (2009) Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials. Pharmacol Res 60:254–26310.1016/j.phrs.2009.03.021 ↗
41. Rossi AC, Hsu JP, Faich GA (1987) Ulcerogenicity of piroxicam: an analysis of spontaneously reported data. Br Med J (Clin Res Ed) 294:147–15010.1136/bmj.294.6565.147 ↗
42. Sahoo SK, Panyam J, Prabha S, Labhasetwar V (2002) Residual polyvinyl alcohol associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 82:105–11410.1016/S0168-3659(02)00127-X ↗
43. Sanders NN, De Smedt SC, Van Rompaey E, Simoens P, De Baets F, Demeester J (2000) Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am J Respir Crit Care Med 162:1905–191110.1164/ajrccm.162.5.9909009 ↗
44. Santoyo S, de Jalón EG, Ygartua P, Renedo MJ, Blanco-Príeto MJ (2002) Optimization of topical cidofovir penetration using microparticles. Int J Pharm 242:107–11310.1016/S0378-5173(02)00178-3 ↗
45. Shojaei AH, Berner B, Li X (1998) Transbuccal delivery of acyclovir: I. In vitro determination of routes of buccal transport. Pharm Res 15:1182–118810.1023/A:1011927521627 ↗
46. Silva GA (2008) Nanotechnology approaches to crossing the blood–brain barrier and drug delivery to the CNS. BMC Neurosci 9:S410.1186/1471-2202-9-S3-S4 ↗
47. Vasir JK, Labhasetwar V (2007) Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev 59:718–72810.1016/j.addr.2007.06.003 ↗
48. Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P (2001) Factors and strategies for improving buccal absorption of peptides. Eur J Pharm Biopharm 51:93–10910.1016/S0939-6411(00)00144-2 ↗
49. Weiss B, Schaefer UF, Zapp J, Lamprecht A, Stallmach A, Lehr C-M (2006) Nanoparticles made of fluorescence-labelled poly(l-lactide-co-glycolide): preparation, stability, and biocompatibility. J Nanosci Nanotech 6:3048–305610.1166/jnn.2006.424 ↗
50. Yang Y-Y, Chung T-S, Ping Ng N (2001) Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 22:231–24110.1016/S0142-9612(00)00178-2 ↗
51. Win KY, Feng S-S (2005) Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:2713–272210.1016/j.biomaterials.2004.07.050 ↗
52. Zan J, Jiang G, Lin Y, Tan F, Ding F (2005) Transdermal delivery of piroxicam by surfactant mediated electroporation. Tsinghua Sci Technol 10:542–54710.1016/S1007-0214(05)70115-2 ↗